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OBJECTIVE — The purpose of this study was to identify reproductive risk factors associated
with dysglycemia (diabetes, impaired glucose tolerance, and impaired fasting glucose) in a
contemporary multiethnic population.
RESEARCHDESIGNANDMETHODS — Westudied14,661womenscreenedwithan
oral glucose tolerance test for the Diabetes Reduction Assessment with Ramipril and Rosiglita-
zone Medication (DREAM) trial. Reproductive risk factors were compared in normoglycemic
and dysglycemic women.
RESULTS — Dysglycemia was signiﬁcantly associated with the number of children born
(odds ratio 1.03 per child [95% CI 1.01–1.05]), age (1.05 per year [1.04–1.05]), non-European
ancestry(1.09[1.01–1.17]),preeclampsia/eclampsia(1.14[1.02–1.27]),irregularperiods(1.21
[1.07–1.36]), and gestational diabetes mellitus (GDM) (1.53 [1.35–1.74]). The relationship
between GDM and dysglycemia did not differ across BMI tertiles (P  0.84) nor did the rela-
tionships of other risk factors.
CONCLUSIONS — Reproductive factors, particularly GDM, are associated with dysglyce-
mia in middle-aged women from many ethnicities. Reproductive factors can be used to counsel
youngwomenabouttheirfutureriskofdysglycemia,whereasinmiddleagetheymayhelpscreen
for dysglycemia.
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G
estational diabetes mellitus (GDM)
is a well-known reproductive risk
factor for subsequent type 2 diabe-
tes(1).Otherreproductivefactorssuchas
preeclampsia are associated with insulin
resistanceduringpregnancyandmayalso
increase the subsequent risk for diabetes.
Furthermore, some (2–4) but not all (5)
studies suggest that pregnancy itself is a
risk factor for future type 2 diabetes. For
example, a population-based study of
1,186 elderly women showed that, even
afteraccountingforage,obesity,andfam-
ily history of diabetes, parity was associ-
ated with an increased risk of type 2
diabetes, with an odds ratio (OR) of 1.16
per pregnancy (95% CI 1.04–1.20) (3).
An even larger study comprising 2,310
womenwithtype2diabetesreportedthat
paritygreaterthansixwasassociatedwith
a relative risk (RR) of diabetes of 1.56
(95% CI 1.27–1.91); however, the esti-
mate of the RR decreased to 1.19 (0.97–
1.48)afteradjustmentforcurrentage(2).
Theapplicabilityoftheseresultsislimited
by the homogeneity of the population
(registered nurses with relatively high so-
cioeconomic status and 98% Caucasian)
and the use of the older fasting plasma
glucose cutoff for diabetes of 7.8
mmol/l(140mg/dl)ratherthanthecur-
rent, more sensitive value of 7.0 mmol/l
(126 mg/dl) (6).
The prevalence of dysglycemia (type
2 diabetes, impaired glucose tolerance
[IGT], and impaired fasting glucose
[IFG]) is increasing; however, reproduc-
tive risk factors are often underrecognized.
In particular, their association with the
more recently recognized forms of glucose
dysregulation, IGT and IFG, have not yet
been well studied. The detection of dys-
glycemiacouldbeimprovedifriskfactors
were better known. Moreover, if repro-
ductive factors such as parity and pre-
eclampsiaareriskfactorsfordysglycemia,
they could be used to reﬁne screening ap-
proaches. The goal of this research was to
identify reproductive risk factors for dys-
glycemia in a contemporary, multiethnic
group of women.
RESEARCH DESIGN AND
METHODS— This is a study of
14,661 women screened as possible par-
ticipants in the Diabetes Reduction As-
sessmentwithRamiprilandRosiglitazone
Medication (DREAM) trial (7,8), a large,
international, multicenter, randomized,
double-blind,controlleddiabetespreven-
tion trial. Participants were volunteers
recruited from 21 countries on ﬁve conti-
nents from a wide variety of sources in-
cluding ﬁrst-degree relatives of diabetic
individuals in diabetes clinics, ads in
newspapers, pharmacies, national diabe-
tesassociations,newsletters,clinics,com-
munity announcements, screening
programs, and targeted mailings. Institu-
tional research ethics boards at each site
approved the DREAM trial.
Assessment
After an overnight (8–18 h) fast, partici-
pants consumed 75 g anhydrous glucose
and provided fasting and 2-h blood sam-
ples for local measurement of plasma glu-
cose. At the same time they completed a
12-page questionnaire regarding baseline
characteristics,medications,andpersonal
and family history, and women com-
pleted a 1-page reproductive question-
naire regarding regularity of menstrual
cycles, fertility, how many children they
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pregnancy including GDM, preeclamp-
sia, or eclampsia.
Deﬁnitions
Type 2 diabetes was deﬁned as fasting
plasma glucose 7.0 mmol/l (126 mg/
dl) or plasma glucose 11.1 mmol/l
(200mg/dl)2haftera75-goralglucose
load. IGT was deﬁned as plasma glucose
7.8–11.0 mmol/l (140–199 mg/dl) 2 h
after a 75-g oral glucose load. IFG was
deﬁned as fasting glucose of 6.1–6.9
mmol/l (110–124 mg/dl). Dysglycemia
was deﬁned as IFG, IGT, or type 2 diabe-
tes. Parity was deﬁned as the number of
infants a woman had borne. Irregular
menses was deﬁned as six or fewer men-
strual cycles per year between the ages of
18 and 45 years not including pregnancy
and was used as a surrogate for polycystic
ovary syndrome. Early menopause was
deﬁned as the permanent cessation of
menstrual periods before age 45. Income
range tables with ﬁve strata were devel-
oped speciﬁc to each country in which
recruitmentoccurred;lowsocioeconomic
status was deﬁned as the lowest strata for
thatcountry.InCanada,forexample,that
included a household income $29,999
and for the U.S. it was $15,400. Non-
European ancestry was deﬁned as anyone
indicating any ancestry other than Euro-
pean at the time of their clinic visit.
Statistical analysis
Women were classiﬁed as those with and
without dysglycemia. Continuous vari-
ables were compared using a t test, and
categorical variables were compared with
a 
2 test. Logistic regression was used to
calculate age-adjusted ORs and 95% CI
for reproductive risk factors for dysglyce-
mia. Factors that were statistically signif-
icant at P  0.10 in the age-adjusted
analysis were included in the multivariate
logistic regression to determine their in-
dependent relationship with prevalent
dysglycemia. This model was rerun for
each tertile of BMI (and P values for het-
erogeneity were calculated) to determine
whether the risk of dysglycemia for each
risk factor varied with BMI. All P values
are reported as two-tailed. All analyses
were performed using SAS software (ver-
sion 9.1; SAS Institute, Cary, NC).
RESULTS— Table 1 presents the base-
line characteristics of the women with (n
6, 298) and without (n8, 363) dysglyce-
mia, whose 2-h plasma glucose concentra-
tions were 10.0  3.1 versus 5.7  1.1
mmol/l, respectively (P  0.0001), with
fasting values of 6.3 1.4 versus 5.0 1.1
mmol/l(P0.0001,respectively).Women
with dysglycemia were signiﬁcantly older
than those without dysglycemia (55.1 vs.
50.0 years, respectively, P0.0001). After
adjustment for age, most of the reproduc-
tive factors remained signiﬁcantly associ-
ated with dysglycemia, including the
number of children a woman gave birth to
(OR 1.05 per child [95% CI 1.04–1.06]), a
history of preeclampsia/eclampsia (1.19
[1.07–1.32]), irregular menses (1.2 [1.09–
1.38]), GDM (1.58 [1.40–1.78]), low so-
cioeconomicstatus(1.09[1.01–1.17]),and
non-European ancestry (1.10 [1.02–1.17])
(Table 1).
In a multivariate model that included
age, ancestry, and fertility-related factors,
dysglycemia was signiﬁcantly associated
with the number of children a woman
gave birth to (OR 1.03 per child [95% CI
1.01–1.05]), age (1.05 per year [1.04–
1.05]), non-European ancestry (1.09
[1.01–1.17]), a history of preeclampsia/
eclampsia (1.14 [1.02–1.27]), irregular
menses (1.21 [1.07–1.36]), and GDM
(1.53 [1.35–1.74]) (Fig. 1). Early meno-
pause (1.24 [0.98–1.53]) and low socio-
economic status (0.95 [0.88–1.02]) were
no longer signiﬁcantly associated with
dysglycemia.
To determine whether there was an
interaction between BMI and the repro-
ductiveriskfactors,particularlyGDM,we
reran the multiple regression model for
each tertile of BMI, with 27.1 and 32.2
deﬁning lower, middle, and upper levels.
The relationships between GDM and cur-
rent dysglycemia did not differ signiﬁ-
cantly across tertiles of BMI (Pheterogeneity
 0.84), nor for any of the other risk fac-
tors (Pheterogeneity 0.10 for all). The ORs
for GDM and current dysglycemia for
each tertile of BMI (27.1, 27.1–32.2,
and 32.2) were 1.81 [95% CI 1.42–
2.30],1.44[1.14–1.81],and1.47[1.20–
1.81], respectively.
CONCLUSIONS — This large, mul-
tiethnic study of middle-aged women
showedthatahistoryofGDMisindepen-
dently associated with prevalent dysgly-
cemia, conﬁrming that pregnancy is a
“stress test for life” (9,10). This observa-
tionmaybeunderstoodinlightofthefact
that the occurrence of GDM is clear evi-
dence of an impaired ability to maintain
normoglycemia under the metabolic
stress of pregnancy and is consistent with
previous reports (11–14) from smaller
studies.Hence,inyoungwomenofchild-
bearing age, reproductive factors, partic-
ularly GDM, can be used to counsel










Age (years) 55.1  11.1 50.0  10.0 0.0001 NA
Number of children 2.74  1.6 2.53  1.3 0.0001 1.05 (1.04–1.06)
Low socioeconomic states 2,243 (37.7) 2,636 (33.2) 0.0001 1.09 (1.01–1.17)
Non-European ancestry 3,339 (53.0) 4,649 (55.6) 0.002 1.10 (1.02–1.17)
Preeclampsia/eclampsia 700 (11.0) 853 (10.1) 0.10 1.19 (1.07–1.32)
Irregular periods 608 (9.6) 734 (8.8) 0.08 1.22 (1.09–1.38)
GDM 588 (9.4) 673 (8.1) 0.01 1.58 (1.40–1.78)
Early menopause 124 (2.0) 217 (2.6) 0.01 1.24 (0.99–1.56)
BMI (kg/m
2) 31.6  6.0 29.4  6.0 0.0001 1.06 (1.06–1.07)
Data are means  SD and n (%) unless otherwise indicated. Dysglycemia indicates IFG, IGT, or type 2 diabetes, irregular periods indicates 6 menstrual cycles per
year between the ages of 18 and 45 years not including pregnancy, and early menopause indicates permanent cessation of menses 45 years of age. NA, not
applicable.
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cemia regardless of future BMI, whereas
inmiddle-agedwomenahistoryofrepro-
ductive risk factors may be useful as a
screening tool for dysglycemia.
This study also showed that a history
of a variety of reproductive risk factors,
including irregular menses, parity, and
preeclampsia, was independently associ-
ated with dysglycemia and was not
explained by age, ethnicity, or socioeco-
nomic status. One potential explanation
is the association of many of these factors
with insulin resistance, including pre-
eclampsia (15,16), pregnancy (17), and,
even in nonobese women, polycystic
ovary syndrome (PCOS) (of which irreg-
ular menses is a key component) (18–
21).
This is the only study, to our knowl-
edge, examining reproductive risk factors
for dysglycemia involving a broad popu-
lation, allowing for wide applicability of
results. Participation spanned all socio-
economic strata and involved 21 coun-
tries on ﬁve continents. Another strength
is the large sample size (14, 661 women),
byfarthelargeststudyintheliteratureon
reproductive risk factors and dysglyce-
mia, which allowed for control of multi-
ple confounding factors. Another
strength is the fact that reproductive risk
factorsthatidentiﬁedwomenatincreased
risk of dysglycemia were elicited with
simple screening questions, which are
part of a routine history, and do not re-
quire serology or imaging investigations
such as pelvic ultrasound. Participants
were asked, for instance, about irregular
menses as a surrogate for PCOS, as PCOS
remains undiagnosed in many patients or
theyareunfamiliarwiththemedicalterm.
Although this approach has the potential
for misclassifying some patients who had
had fertility-related risk factors as being
unaffected, it suggests that the associa-
tions between fertility-related risk factors
anddysglycemiaareprobablyevenstron-
ger than those observed.
Limitations of the study include the
fact that the participants were asked to
recall events, such as pregnancies, which
in many instances occurred several de-
cades earlier. However, by gathering this
baseline information before the adminis-
tration of the oral glucose tolerance test,
recall bias was limited. We did not have
access to the participants’ medical charts
and relied on patient history, which may
not always be reliable and may underesti-
mate some of the above associations.
Insummary,inthislarge,multiethnic
study of middle-aged women without a
previous diagnosis of diabetes, prevalent
dysglycemia was independently associ-
atedwithahistoryofseveralreproductive
risk factors, particularly GDM. Moreover,
the relationship between prior GDM and
current dysglycemia persisted across BMI
strata.
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